Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma

Approximately 50% of melanomas harbor an activating BRAF mutation. Combined BRAF and MEK inhibitors such as dabrafenib and trametinib, vemurafenib and cobimetinib, and encorafenib and binimetinib are US Food and Drug Administration (FDA)-approved to treat patients with BRAF(V600)-mutated advanced me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Onco Targets Ther
Main Authors: Kakadia, Sunilkumar, Yarlagadda, Naveen, Awad, Ramez, Kundranda, Madappa, Niu, Jiaxin, Naraev, Boris, Mina, Lida, Dragovich, Tomislav, Gimbel, Mark, Mahmoud, Fade
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2018
Assuntos:
Review
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6200076/
https://ncbi.nlm.nih.gov/pubmed/30410366
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S182721
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados